Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Latest News about Phase 3 Trial
Recent news which mentions Phase 3 Trial
< Previous
1
2
3
4
5
6
7
8
Next >
Scynexis Aces Ibrexafungerp Late-Stage Study To Prevent Vaginal Yeast Infections
February 10, 2022
Tickers
SCYX
Tags
General
Benzinga
Market News
From
Benzinga
Alkermes Schizophrenia Med Shows Lower Mean Weight Gain In Early Illness With Schizophrenia
February 08, 2022
Tickers
ALKS
Tags
Market News
News
General
From
Benzinga
Cingulate Outlines Plan For Pivotal Attention Deficit/Hyperactivity Disorder Studies
February 08, 2022
Tickers
CING
Tags
Penny Stocks
Biotech
CING
From
Benzinga
Why Are Vanda Pharma Shares Plunging Today?
February 04, 2022
Tickers
VNDA
Tags
General
Market News
News
From
Benzinga
Anavex Life Sciences Says Rett Syndrome Trial Meets Primary & Secondary Goals
February 01, 2022
Tickers
AVXL
Tags
General
News
Market News
From
Benzinga
Valneva Kickstarts Phase 3 Trial Of Chikungunya Vaccine Candidate In Adolescents
February 01, 2022
Tickers
VALN
Tags
Chikungunya
Biotech
Health Care
From
Benzinga
Madrigal Pharma's Kidney Disease Candidate Improves Liver, Cardiovascular Health
January 31, 2022
Tickers
MDGL
Tags
General
Market News
News
From
Benzinga
Why Are Tyme Technologies Shares Staring At 52-Week Low
January 26, 2022
Tickers
TYME
Tags
Briefs
Trading Ideas
Health Care
From
Benzinga
FDA Guides Annovis Bio For Two Phase 3 Buntanetap Trial In Parkinson's Disease
January 25, 2022
Tickers
ANVS
Tags
Biotech
General
Parkinson’s Disease
From
Benzinga
Achieve Life Sciences Initiates Pivotal Trial Of Cytisinicline For Smoking Cessation
January 25, 2022
Tickers
ACHV
Tags
Briefs
Biotech
Health Care
From
Benzinga
Sierra Oncology Shares Rally As Bone Marrow Cancer Candidate Hits Primary Goal
January 25, 2022
Tickers
SRRA
Tags
Health Care
Trading Ideas
Briefs
From
Benzinga
Lyra Therapeutics Kickstarts LYR-210 Pivotal Program in Surgically Naïve Chronic Rhinosinusitis Patients
January 24, 2022
Tickers
LYRA
Tags
News
Market News
LYRA
From
Benzinga
On Positive Virology Data, SAB Biotherapeutics' COVID-19 Drug To Move To Phase 3 In NIH ACTIV-2 Trial
January 24, 2022
Tickers
SABS
Tags
Biotech
General
COVID/19 Coronavirus
From
Benzinga
FDA Approves Gilead's Remdesivir For Non-Hospitalized COVID-19 Patients At High Risk For Disease Progression
January 24, 2022
Tickers
GILD
Tags
General
Benzinga
COVID/19 Coronavirus
From
Benzinga
UCB's Bispecific Marks Phase 3 Win For Second Psoriatic Arthritis Study
January 21, 2022
Tickers
UCBJF
UCBJY
Tags
Health Care
Biotech
Briefs
From
Benzinga
Alnylam' Reveals Detailed 18-Month Data From Vutrisiran Trial In Inherited Disease
January 21, 2022
Tickers
ALNY
Tags
Phase 3 Trial
Briefs
Health Care
From
Benzinga
KemPharm To Develop KP1077 As Lead SDX Candidate For Chronic Sleep Disorder
January 20, 2022
Tickers
KMPH
Tags
Briefs
Health Care
Phase 3 Trial
From
Benzinga
Seres Therapeutics' Oral Microbiome Candidate Shows Meaningful Improvements In Difficile Infection
January 20, 2022
Tickers
MCRB
Tags
Briefs
Health Care
Trading Ideas
From
Benzinga
EQRx's Sugemalimab Shows Significant Overall Survival Benefit In Lung Cancer Settings
January 19, 2022
Tickers
EQRX
Tags
Health Care
Non/Small Cell Lung Cancer
Biotech
From
Benzinga
Second Dupixent Phase 3 Trial Confirms Significant Improvements In Inflammatory Skin Disease
January 19, 2022
Tickers
REGN
SNY
Tags
Phase 3 Trial
REGN
Biotech
From
Benzinga
Merck's Keytruda Manages To Cross The Finish Line In Liver Cancer Confirmatory Trial
January 19, 2022
Tickers
MRK
Tags
Briefs
FDA
Health Care
From
Benzinga
RedHill Biopharma's Oral COVID-19 Treatment Improves Median Time To Viral RNA Clearance
January 13, 2022
Tickers
RDHL
Tags
Briefs
RDHL
Health Care
From
Benzinga
Merck's Keytruda As Adjuvant Treatment Improves Disease-Free Survival In Lung Cancer Setting
January 10, 2022
Tickers
MRK
Tags
Phase 3 Trial
Briefs
Biotech
From
Benzinga
FDA Gives Green Signal To Reviva Pharma's Late-Stage Schizophrenia Trial
January 10, 2022
Tickers
RVPH
Tags
why it's moving
News
RVPH
From
Benzinga
Oncternal, FDA In Pact For Pivotal Study Design For Zilovertam In Mantle Cell Lymphoma
January 05, 2022
Tickers
ONCT
Tags
Market News
why it's moving
News
From
Benzinga
Early Data Shows Novavax's COVID-19 Vaccine Triggers Immune Response To Omicron
December 23, 2021
Tickers
NVAX
Tags
Movers
Phase 3 Trial
Trading Ideas
From
Benzinga
Gilead's Remdesivir Shows Consistent Efficacy In Patients With Comorbidities With Higher Risk for Severe COVID-19
December 23, 2021
Tickers
GILD
Tags
Phase 3 Trial
GILD
Briefs
From
Benzinga
Allakos' Shares Nosedive After Lirentelimab Studies Fail To Achieve Statistical Significance On Symptomatic Endpoints
December 22, 2021
Tickers
ALLK
Tags
Movers
Phase 3 Trial
Health Care
From
Benzinga
Valneva Posts Positive Lot-to-Lot Consistency Data For Its Single-Dose Chikungunya Vaccine
December 22, 2021
Tickers
VALN
Tags
News
Market News
General
From
Benzinga
DBV Technologies To Conduct New Pivotal Trial For Peanut Allergy Patch, Shares Plunge To 52-Week Low
December 21, 2021
Tickers
DBVT
Tags
Biotech
Penny Stocks
General
From
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.